M-A: Tirzepatide cardiovascular event risk assessment.
18 May, 2022 | 10:34h | UTCTirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Commentary: Meta-analysis backs tirzepatide CV safety – medwireNews
Commentary on Twitter
A meta-analysis of cardiovascular secondary outcomes from the SURPASS program, testing efficacy of a new novel dual GIP/GLP-1 receptor agonist tirzepatide, demonstrates cardiovascular safety in patients with type 2 #diabetes https://t.co/xQBbj3Egkg
— Nature Medicine (@NatureMedicine) February 25, 2022